BPC-157 vs Humanin
Side-by-Side Comparison
| Attribute | Bpc 157 | Humanin |
|---|---|---|
| Category | Healing & Recovery | Metabolic / Mitochondrial |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Humanin operates through both intracellular and extracellular mechanisms. Intracellularly, it binds pro-apoptotic proteins BAX, Bim, and tBid to inhibit caspase activation and cell death. |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Preclinical. No completed clinical trials. Epidemiological studies show correlation with longevity. |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | No formal human safety data; Endogenous peptide — naturally present in human circulation |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Subcutaneous or Intraperitoneal (research) |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | No established human dose. HNG (S14G variant) active at nanomolar concentrations. Mouse studies: 0.2-4 mg/kg IP. |
| Frequency | Once daily | Once daily (animal protocols) |
| Molecular Weight | ~1419.5 g/mol | ~2,687 g/mol (24 aa form) |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | Minutes in plasma (rapid degradation) |
Overview
BPC-157 and Humanin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Humanin — Mechanism & Evidence
Humanin is a 21-24 amino acid mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. It was originally discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity. Since then, it has been found to have broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Circulating humanin levels decline with age and correlate with longevity in centenarian studies.
Key claims: Neuroprotection against Alzheimer's toxicity; Cardioprotection; Improves insulin sensitivity.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Humanin targets Anti-Aging, Cognitive Enhancement.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Humanin: No formal human safety data Endogenous peptide — naturally present in human circulation No adverse effects reported in animal studies at tested doses
Related Products
Related Research News
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.
Anti-Aging Peptides: Research Compounds for Metabolism, Muscle, and Tissue Health
Explore a curated selection of anti-aging research peptides including BPC-157, GHK-CU, KPV, MOTS-C, NAD+, Retatrutide, SS-31, TB-500, and others. These compounds are studied for their potential roles in metabolism support, muscle growth, weight loss, and skin, tissue, and bone health. Average purity across products is 99.77%.